DJ Edison Investment Research Limited: Edison issues initiation on Oasmia Pharmaceutical (OASM)
Edison Investment Research Limited
Edison Investment Research Limited: Edison issues initiation on Oasmia
Pharmaceutical (OASM)
09-Sep-2020 / 14:59 GMT/BST
London, UK, 9 September 2020
Edison issues initiation on Oasmia Pharmaceutical (OASM)
Oasmia is a specialty pharma company focused on developing improved
formulations of well-established cancer drugs through its proprietary XR-17
platform technology. Its technology has received validation though a global
partnership deal for lead asset Apealea (Cremophor-free paclitaxel) with
Elevar Therapeutics across a variety of cancer indications. Apealea's
initial indication is ovarian cancer (approved in Europe), and Elevar is in
discussions with the FDA for the pathway to US approval (we forecast launch
in FY23). Oasmia's newly appointed management has defined a strategy to
realign the business, further leverage on its platform competencies and
expand its pipeline through acquisitions as it moves to the ultimate goal of
sustainable profitability. We value Oasmia at SEK2.82bn or SEK6.29/share.
We initiate coverage with a valuation of SEK2.82bn or SEK6.29/share
including net cash of SEK274m, based on a risk-adjusted model of the future
royalties and milestones we expect for Apealea (ovarian cancer only),
docetaxel micellar (prostate cancer) and an indicative value for the animal
health business. We do not include the XR-17 platform, or other cancer
indications in our valuation.
Click here [1] to view the full report.
Subscribe [2]to Edison's content to receive reports by email.
All reports published by Edison are free-to-access and available on the
website [3].
About Edison: Edison is an investment research and advisory company, with
offices in North America, Europe, the Middle East and AsiaPac. The heart of
Edison is our world-renowned equity research platform and deep multi-sector
expertise. At Edison Investment Research, our research is widely read by
international investors, advisers and stakeholders. Edison Advisors
leverages our core research platform to provide differentiated services
including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority [4].
Edison is not an adviser or broker-dealer and does not provide investment
advice. Edison's reports are not solicitations to buy or sell any
securities.
For more information please contact Edison:
Dr Susie Jana, +44 (0)20 3077 5700
Dr John Priestner, +44 (0)20 3077 5700
healthcare@edisongroup.com [5]
Learn more at www.edisongroup.com [6] and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-group- [7]
Twitter www.twitter.com/Edison_Inv_Res [8]
YouTube www.youtube.com/edisonitv [9]
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
1129477 09-Sep-2020
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=2565376f391962de29235902ddb7765f&application_id=1129477&site_id=vwd&application_name=news
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=dc4b6da9609a3fa15934b7007f0912b2&application_id=1129477&site_id=vwd&application_name=news
3: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=2d62d350e44141e01d1766d8ed0b3f95&application_id=1129477&site_id=vwd&application_name=news
4: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=105fe9be9b5e36892886e5a39d51d4b7&application_id=1129477&site_id=vwd&application_name=news
5: mailto:financials@edisongroup.com'subject=Re:%20Palace%20capital
6: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=88c95533002fab2316572f9ef6cf3cc6&application_id=1129477&site_id=vwd&application_name=news
7: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=afe662765000a80ab72afd922939c992&application_id=1129477&site_id=vwd&application_name=news
8: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=ec2d264fe4f303e2143a2e85c6eaa823&application_id=1129477&site_id=vwd&application_name=news
9: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=6b959e4d7ee3c402b931a274d2bbe945&application_id=1129477&site_id=vwd&application_name=news
(END) Dow Jones Newswires
September 09, 2020 09:59 ET (13:59 GMT)
